Artax Biopharma is a clinical-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. We are developing the next generation of drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. Highly selective control over T-cells through TCR provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.
